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http://www.trialsjournal.com/content/14/1/152STUDY PROTOCOL Open AccessGoal-oriented cognitive rehabilitation
in early-stage dementia: study protocol
for a multi-centre single-blind randomised
controlled trial (GREAT)
Linda Clare1*, Antony Bayer2, Alistair Burns3, Anne Corbett4,5, Roy Jones6, Martin Knapp7,5, Michael Kopelman5,
Aleksandra Kudlicka1, Iracema Leroi3, Jan Oyebode8, Jackie Pool9, Bob Woods1 and Rhiannon Whitaker1Abstract
Background: Preliminary evidence suggests that goal-oriented cognitive rehabilitation (CR) may be a clinically
effective intervention for people with early-stage Alzheimer’s disease, vascular or mixed dementia and their carers.
This study aims to establish whether CR is a clinically effective and cost-effective intervention for people with
early-stage dementia and their carers.
Methods/design: In this multi-centre, single-blind randomised controlled trial, 480 people with early-stage
dementia, each with a carer, will be randomised to receive either treatment as usual or cognitive rehabilitation
(10 therapy sessions over 3 months, followed by 4 maintenance sessions over 6 months). We will compare the
effectiveness of cognitive rehabilitation with that of treatment as usual with regard to improving self-reported and
carer-rated goal performance in areas identified as causing concern by people with early-stage dementia;
improving quality of life, self-efficacy, mood and cognition of people with early-stage dementia; and reducing stress
levels and ameliorating quality of life for carers of participants with early-stage dementia. The incremental
cost-effectiveness of goal-oriented cognitive rehabilitation compared to treatment as usual will also be examined.
Discussion: If the study confirms the benefits and cost-effectiveness of cognitive rehabilitation, it will be important
to examine how the goal-oriented cognitive rehabilitation approach can most effectively be integrated into routine
health-care provision. Our aim is to provide training and develop materials to support the implementation of this
approach following trial completion.
Trial registration: Current Controlled Trials ISRCTN21027481
Keywords: Alzheimer’s disease, Vascular dementia, Mixed dementia, Re-ablement, Quality of life, Cost-effectivenessBackground
There is a greater need than ever before to identify ef-
fective and beneficial interventions for people with
early-stage dementia. There are thought to be over
750,000 people with dementia in the UK, a figure that is
expected to have doubled by 2040 [1,2]. Current policy
targets include ensuring early diagnosis and good quality
early intervention for all and supporting people with de-
mentia in living as full and active a life as possible [1].* Correspondence: l.clare@bangor.ac.uk
1School of Psychology, Bangor University, Bangor, Gwynedd LL57 2AS, UK
Full list of author information is available at the end of the article
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reproduction in any medium, provided the orEarly diagnosis of dementia creates an opportunity to
equip patients and carers to manage the disease effect-
ively and to live well with dementia [3]. In this context
early intervention offers the possibility of reducing or
delaying the progression of functional disability, depres-
sion or behavioural difficulties, helping to maintain inde-
pendence, supporting management of co-morbidity and
hence avoiding or reducing hospitalisation, maintaining
quality of life and ultimately delaying institutionalisation.
At present, however, the chances of accessing early psy-
chosocial intervention following a diagnosis of dementia
are low, and research evidence regarding the efficacy ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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priorities set out by the Ministerial Advisory Group on
Dementia Research (MAGDR) in 2011 indicate a need to
evaluate the effect of psychosocial interventions for people
with dementia living in the community, including those
based on ‘re-ablement’, and to identify ways of improving
quality of life for people with dementia and their carers.
Relatively little attention has been given to developing
psychosocial early intervention approaches aimed at help-
ing people to live well with dementia. Traditionally, efforts
have focussed instead on attempting to address the under-
lying impairments in memory and other cognitive func-
tions, which are a defining feature of early-stage dementia.
A number of research studies have examined the potential
of cognitive training to benefit people with dementia. Cog-
nitive training involves repeated, structured practice on
tasks targeting specific cognitive domains, such as working
memory or attention. Evidence is mixed, with some stud-
ies reporting modest benefits and others reporting no ben-
efits, but a Cochrane systematic review [4] found no
evidence for significant benefits. Even where improve-
ments on cognitive tasks assessing trained domains are
reported, there is no evidence that these generalise to
other areas, have any impact in the real-life context or
offer any benefits as regards engagement in everyday activ-
ities [5]. That is to say, these approaches, which target
underlying impairment, albeit with limited success, fail to
reduce functional disability. Yet there is evidence for pres-
ervation of some degree of cognitive and neural plasticity
in early-stage dementia [6], and it should be possible to
harness this potential to deliver beneficial intervention ef-
fects. According to neuropsychological models of memory
[7], while some cognitive functions (e.g. long-term epi-
sodic recall) are significantly impaired in early-stage
Alzheimer’s disease, others are relatively spared (e.g. pro-
cedural memory for skills, routines and actions, semantic
knowledge and implicit memory) [8], and people with
early-stage dementia are capable of some new verbal and
behavioural learning [9], although they are likely to require
extra support to achieve it [10]. Consequently, there are
possibilities for behaviour change to occur.
Conceptualising dementia within the framework of a
disability model [11,12] highlights the distinction between
the underlying impairment, resulting from pathological
changes, and the resulting limitations on engaging in ac-
tivity (disability) and restrictions on social participation
(handicap). Activity limitation and participation restriction
are not solely determined by the degree of impairment,
but are subject to a range of personal, social and environ-
mental influences. Negative influences can contribute to
the development and maintenance of ‘excess’ disability
[13], where the extent of functional disablement is greater
than would be predicted by the degree of impairment; an
example would be where an individual loses confidence,gives up previously enjoyed activities, and becomes so-
cially withdrawn and depressed in reaction to receiving
the diagnosis of dementia, with consequent effects on cog-
nitive and functional ability. This is similar to Kitwood’s
description of the way in which a negative, unsupportive
social environment can undermine well-being for people
with dementia [14]. Equally, positive influences can sup-
port optimal functioning and overcome some of the po-
tential impact of impairment, enabling people to live well
with dementia. A focus on addressing barriers to activity
and participation, and encouraging adaptive behaviours,
can therefore be expected to produce benefits for people
with dementia and their family members.
Interventions that aim to reduce functional disability by
targeting activity and participation, drawing on retained
strengths to support adaptive behaviour, are typically de-
scribed as forms of rehabilitation. Rehabilitation interven-
tions aim to ‘enable people who are disabled by injury or
disease to achieve their optimum physical, psychological
[and] social well-being’ [15]. The rehabilitation of people
who have cognitive, as opposed to purely physical, impair-
ments is termed ‘cognitive rehabilitation’ (CR) [16]. Al-
though rehabilitation is most often associated with non-
progressive conditions such as brain injury, it is equally
applicable to people with chronic and progressive condi-
tions. There is considerable evidence for the efficacy of
cognitive rehabilitation with a range of clinical groups
[17]. Rehabilitation interventions are generally highly
individualised, as clients have a diverse range of impair-
ments, needs, circumstances and preferences. Central to
the practice of rehabilitation is the identification of realis-
tic and personally meaningful individual rehabilitation
goals for each client and the development of tailored inter-
ventions to address these. Goal-based approaches have
been applied in numerous conditions, including brain in-
jury [18,19], stroke [20], neurological illness [21], physical
disability [22] and chronic pain [23,24], as well as for frail
older people [25]. Goals are, wherever possible, negotiated
collaboratively between client and therapist. Such inter-
ventions may be regarded as inherently person-centred.
It has been suggested that rehabilitation provides a useful
overarching conceptual framework for the care and support
of people with dementia and for the design of interventions
to meet their needs [26]. A few early examples of interven-
tions that addressed meaningful individual goals relating to
self-care or activity participation supported the possible
utility of this approach [27,28]. Hence feasibility studies
were undertaken to explore the application of cognitive re-
habilitation to help people with early-stage dementia and
their families manage the impact of the condition.
A series of studies using single-case experimental de-
signs or small-group pre/post comparisons demonstrated
that it was possible to identify meaningful personal goals
and use evidence-based restorative or compensatory
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change in these areas for people with early-stage dementia
[31-34]. Restorative approaches build on retained abilities
and use a range of instructional or prompting techniques
to promote new learning or relearning, whether of infor-
mation, habits or strategies; examples include the applica-
tion of the spaced retrieval method to support retention of
information [35]. Compensatory methods use a range of
aids and adaptations to support functioning and overcome
limitations resulting from cognitive impairments; exam-
ples include the use of memory books to support engage-
ment in conversation [36]. Rehabilitation interventions for
people with dementia need to offer practical benefits in
daily life. In the context of cognitive impairment it is par-
ticularly challenging to ensure that learning and behav-
ioural change generalises from one setting to another; to
circumvent this obstacle, the interventions in our small-
scale studies were carried out in the person’s everyday set-
ting rather than in the clinic. The behavioural changes ob-
served, although focused on specific targeted goals, led to
wider benefits in everyday life; for example, learning
names of other participants in a social club helped to
maintain attendance and participation and reduced the
risk of social isolation [31], and using a memory aid to re-
duce repetitive questioning reduced carer frustration and
tensions between the participant and carer [32]. There
was also some evidence for generalisation of the problem-
solving approach to other everyday situations and chal-
lenges [32,33]. Gains were maintained for several months
post-intervention, and one longer-term study demon-
strated maintenance of gains up to 3 years post-
intervention [37]. Further studies investigated the efficacy
and applicability of specific memory rehabilitation tech-
niques, such as errorless learning and spaced retrieval
methods [38-40]. These findings were augmented by re-
ports from other research groups [41,42]. A Cochrane sys-
tematic review found no randomised controlled trials of
cognitive rehabilitation [4]. The findings from the feasibil-
ity studies, therefore, formed the basis for developing an
intervention protocol that could be tested in a pilot
randomised controlled trial [34].
The design of trials to evaluate the efficacy of rehabili-
tation interventions must take into account the fact that
rehabilitation typically focuses on the attainment of
highly individual goals that are functionally, socially and
contextually relevant [43]. When evaluating service or
programme outcomes in rehabilitation settings, goal at-
tainment scaling has been used to identify goals and rate
progress on a standardised scale [18,25,43,44]. However,
where the focus is on treatment outcomes for the indi-
vidual client, as opposed to overall efficacy of a multidis-
ciplinary or multi-component programme, goal setting
and goal achievement are more readily evaluated by
means of client-centred approaches in which the clientplays a central role in a collaborative goal-setting process,
and the client’s perceptions of change serve as the primary
outcome measure. The most widely used example of this
approach is provided by the Canadian Occupational Per-
formance Measure (COPM) [45], which offers a struc-
tured format for eliciting individual goals and a
standardised means of rating goal performance and satis-
faction with performance. There is evidence for the reli-
ability, construct validity, sensitivity and responsiveness of
this measure as well as for its clinical utility [20,46-51].
When using this measure in research, it is possible to elicit
goals and performance ratings at baseline and to have par-
ticipants in both treatment and control groups re-rate goal
performance at follow-up. Where clients have cognitive
impairments, it is helpful to supplement self-ratings with
independent ratings made by professionals or caregivers
for comparison purposes [20,50]. The goal-oriented ap-
proach accords with person-centred values in dementia
care, allowing the person with dementia to engage in an
intervention that is specifically tailored to his/her own
needs and preferences, while also providing for a
standardised group-level comparison. Therefore, more re-
cently, the Bangor Goal-Setting Interview (BGSI) has been
developed for research purposes [52]. This interview has
similar aims to those of the COPM, but has been devel-
oped primarily as a research tool and incorporates a num-
ber of different features. The BGSI is based on the social
cognitive theory of behaviour change [53] and on the con-
cept of motivational interviewing [54], and the relevant
domains of functioning in relation to which goals will be
considered are selected according to the requirements of
the given study.
The CR intervention is focussed on the identification
and attainment of individual goals. The recently developed
BGSI will be used in the GREAT trial. However, for the
pilot trial, perceived goal performance, rated using the
COPM, was selected as the primary outcome. A pilot trial
of individual, goal-oriented CR, funded by the Alzheimer’s
Society and published in the American Journal of Geriatric
Psychiatry, was conducted in North Wales from 2005 –
2009 [55]. This was a single-site, single-blind randomised
controlled trial comparing an eight-session CR interven-
tion to relaxation therapy (RT), which involved equivalent
therapist time and attention, and was expected to be
pleasurable for participants without addressing the areas
targeted in CR, and to treatment as usual (TAU). All par-
ticipants received acetylcholinesterase-inhibiting (AChEI)
medication and routine outpatient monitoring, and had
access to the range of voluntary sector services available at
the time in the area. The primary outcome was goal per-
formance and satisfaction with performance. Sixty-nine
participants were randomised by computer algorithm, in-
dependently operated by the North Wales Organisation
for Randomised Trials in Health, Clinical Trials Unit
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23; RT, n = 24; TAU, n = 22).
Following intervention, goal performance and satisfaction
ratings improved for the CR group and showed no change
in the other two groups (see Figure 1). Analysis of covari-
ance indicated a significant effect of CR on performance
(F(2,58) = 7.880, P <0.001) and satisfaction (F(2,58) = 8.270,
P < 0.001). For both measures, CR differed significantly to
both RT and TAU (performance: 1.459 ± 0.936 for RT and
1.128 ± 0.989 for TAU; satisfaction: 1.686 ± 1.041 for RT
and 1.193 ± 1.090 for TAU). For the CR group, achieve-
ment of therapy goals was corroborated in three ways
through within-group analyses [56]. First, participants rated
performance and satisfaction with performance for each
goal targeted, recording significant increases (performance:
t(25) = −3.742, P < 0.001; satisfaction: t(25) = −4.877, P <
0.001). Second, a separate therapist rating of goal perform-
ance was made at the start and end of therapy; this
reflected significant improvements (t(25) = −8.027, P <
0.001). Third, a simplified goal attainment scaling proced-
ure was used, whereby for each therapy goal behavioural in-
dicators of full and partial attainment were established by
the research team at the start of therapy and each goal was
rated accordingly at the end of therapy. This classified 12
(46%) goals as fully implemented, 13 (50%) as partially
implemented and 1 (4%) as not implemented. It was noted
that many of the partially implemented goals would likely
have been fully achieved given a little more time.
Secondary outcomes were evaluated in terms of effect
sizes (Cohen’s d) for the CR group compared to the
pooled control (RT and TAU) groups, as no differences
were observed between the two control groups on any
measure. Outcomes examined for the person with de-
mentia were quality of life, mood and cognition (effect
sizes are shown in Table 1). CR produced benefits in all0
1
2
3
4
5
6
7
8
9
10
CR RT
Figure 1 Effects of intervention on goal performance and satisfaction
trial: significant improvements for CR and no change for RT or TAU.three areas, and quality of life continued to improve at
6-month follow-up. It should be noted that for the most
part mood was within the normal range at baseline and
hence scope for improvement was limited. For carers,
CR reduced stress and improved psychological well-
being and quality of life (effect sizes are shown in
Table 1), and in some cases these were maintained or
continued to improve at follow-up.
The CR intervention was acceptable to, and well received
by, participants and carers. Across all three groups, the at-
trition rate between randomisation and post-intervention
assessment was 7%; five individuals discontinued because
of physical illness (1), death (1), incorrect diagnosis (1) and
self-withdrawal (2). Attrition between post-intervention as-
sessment and 6-month follow-up was 12%; eight individ-
uals were lost to follow up because of death (2), moving
out of the area (3) and self-withdrawal (3). Thus, the over-
all rate of elective self-withdrawal for the trial was only 7%
(2 each from CR and RT, and 1 from TAU).
This pilot trial demonstrated that participants with
early-stage dementia can identify personally meaningful
goals relating to managing everyday activities, and, with
a modest amount of support from a therapist, make sig-
nificant progress towards implementing these. Goal per-
formance constituted a sensitive and specific measure of
change. As performance and satisfaction ratings were
closely associated, performance ratings should suffice in
future work. The addition of carer ratings of perform-
ance would be informative. The trial provided valuable
experience in collaborative identification of specific,
measurable, achievable and realistic goals [56]. Results
suggested that a slightly longer intervention might be
advisable in order to fully establish and consolidate
gains. The trial showed that CR can bring benefits with
regard to cognition, well-being and quality of life for theTAU
Performance
initial
Performance
post
Satisfaction
initial
Satisfaction
post
(COPM ratings) for participants in each condition in the pilot
Table 1 Effect sizes (Cohen’s d) on secondary outcome
measures obtained in the pilot trial for the CR group
compared to the pooled RT and TAU groups
Measure Post-
intervention
6-month
follow-up
Participants with dementia
Quality of life (QoL-AD) 0.24 0.29
Depression (HADS) 0.26 0.13
Anxiety (HADS) 0.21 0.11
Memory (RBMT) 0.37 0.08
Verbal fluency (FAS) 0.29 -
Sustained attention (TEA elevator counting) 0.76 -
Auditory selective attention (TEA ECD) 0.53 -
Visual selective attention (TEA map search 1
min)
0.11 -
Everyday problem-solving (ILS) 0.21 -
CARERS
Stress (RSS) 0.54 0.27
Psychological well-being (GHQ) 0.51 0.11
Quality of life: social relationships (WHOQoL) 0.34 0.49
Quality of life: psychological (WHOQoL) 0.11 0.55
Quality of life: physical health (WHOQoL) 0.69 0.38
Quality of life: environment (WHOQoL) 0.46 0.08
HADS Hospital Anxiety and Depression Scale, RBMT Rivermead Behavioural
Memory Test, TEA Test of Everyday Attention, FAS letter fluency for letters F, A,
and S, TEA ECD, TEA elevator counting with distraction, ILS Independent Living
Scales, RSS Relatives’ Stress Scale, GHQ-12, General Health Questionnaire.
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quality of life of the carer. The lack of observed differ-
ences between the two control groups (RT and TAU)
suggested that in a definitive trial TAU could be adopted
as an appropriate comparison condition for CR. Findings
from the pilot provided information about intervention
parameters, outcomes and effect sizes that has informed
the design of the planned multi-site trial presented
below.
Methods/design
This is a multi-centre single-blind randomised con-
trolled trial comparing cognitive rehabilitation (CR) to
treatment as usual (TAU) for people with early-stage
Alzheimer’s, vascular or mixed dementia, with outcomes
assessed at 3 and 9 months post randomisation. Partici-
pants will be recruited from memory clinics, old age
mental health services and general practitioner (GP)
practices. CR will be delivered in participants’ homes,
with a carer involved where possible. The study will be
run from the co-ordinating centre at Bangor University
with six recruiting centres around the UK: North-West
England, South-West England, West Midlands, London,
South Wales and North Wales. At each recruiting centre,a part-time therapist (with an appropriate professional
background, e.g. occupational therapy or psychology) will
conduct the interventions, and a research assistant, blind to
group allocation, will carry out assessments at baseline and
at 3 and 9 months post-randomisation. Participants will be
recruited to the trial between 1 April 2013 and 30 Septem-
ber 2015. A CONSORT-style flow chart for the trial is
shown in Figure 2.
The cognitive rehabilitation intervention
CR is an individualised approach for people with dementia
(PwD) aimed at managing or reducing functional disability
and maximising engagement and social participation.
PwD and their carers work together with a health profes-
sional over a number of sessions to identify personally
relevant goals and devise and implement strategies for
achieving these. CR will be delivered in ten individual ses-
sions over 3 months, followed by four maintenance ses-
sions over 6 months. Carers will be involved in part of
each session where possible. Involvement of a carer helps
to ensure that skills are maintained and applied to novel
situations and facilitates communication about how
current or possible future difficulties might be managed.
Over the course of the 10 weekly sessions, participants
with dementia will work in collaboration with the ther-
apist to address personal rehabilitation goals. Drawing
on the goals identified at baseline assessment, up to
three behavioural goals will be operationalised, and strat-
egies for addressing these will be devised and
implemented. Goals will be introduced one at a time, in
a flexible manner depending on rate of progress. Follow-
ing introduction and modelling of strategies and skills
during the therapy sessions, the participant and carer
will work on the selected goal between sessions follow-
ing an agreed schedule of activities. Progress with each
goal will be reviewed and the strategies adopted will be
adjusted as necessary on a weekly basis. Performance for
each goal will be independently rated at the outset and
in week 10 by the participant, carer and therapist, and
the therapist will rate the extent of goal attainment fol-
lowing the sessions in week 10. Work on goals will be
supplemented by the following components, designed to
support the ability to make progress with the selected
goals and address barriers to progress, which will be sys-
tematically introduced across the ten sessions:
1. Introduction of, and practice in applying, a solution-
focused problem-solving approach by following a
short sequence of steps to specify and test possible
solutions.
2. Introduction of anxiety management strategies,
building on participants’ existing strengths and
preferences in this area, and practice in strategy use
and application.
Figure 2 GREAT trial CONSORT-style flow chart.
Clare et al. Trials 2013, 14:152 Page 6 of 15
http://www.trialsjournal.com/content/14/1/1523. Monitoring of activity levels, leading to plans for
increasing engagement in meaningful and enjoyable
activity, and implementation of these plans.
4. Practice in strategies for maintaining or improving
attention and concentration.
5. A review of compensatory strategy use (e.g.
calendars, diaries, reminder systems) anddevelopment and implementation of plans for
improving strategy use, which might include
increasing the efficiency of existing strategies and
introduction of new strategies.
6. A review of current use of restorative strategies for
retaining new information or improving recall, and
practice in key strategies (mnemonics, semantic
Clare et al. Trials 2013, 14:152 Page 7 of 15
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to identify a preferred strategy and apply this in
everyday situations.
In addition, to ensure sensitivity to the wider context,
where appropriate a discussion of carer well-being and
strategies for managing stress will be initiated, and infor-
mation will be provided about additional sources of sup-
port and help, with encouragement to access these. The
four maintenance sessions will focus on supporting
maintenance of gains and encouraging continued goal
performance and strategy use. The therapist will re-rate
the extent of goal attainment following the session in
week 14.
The effects of the CR intervention will be compared to
treatment as usual (TAU). In the pilot, CR was compared
with TAU and with an attention placebo condition (relax-
ation therapy). There was no evidence of a difference be-
tween the two control groups, which suggests that TAU
can serve as an appropriate comparator. For the CR group,
the CR will be provided in addition to TAU, while the con-
trol group will receive only TAU and will have no contact
with the research team between assessments. TAU will
consist of acetylcholinesterase-inhibiting medication where
prescribed, and any other services normally provided apart
from specific programmes of cognitive rehabilitation or
other cognition-focused intervention. TAU may include,
for example, routine monitoring by the Memory Clinic, in-
formation provision, attendance at drop-in groups or sup-
port groups, or carer participation in support groups.
Service receipt during the intervention period, including
dementia-specific services, monitoring and interventions
provided by Memory Clinics, will be documented for all
participants. All participants will be free to access services
such as those offered by the Alzheimer’s Society, and the
extent of this will be recorded.
Participant selection
Participants will be recruited from memory clinics, old
age mental health services and GP practices, and will
have been diagnosed with early-stage Alzheimer’s disease
(AD), vascular dementia, or mixed AD and vascular de-
mentia. For each participant, a carer (a family member
or close friend who is either co-resident or in regular
contact) will also be involved.
Inclusion criteria:
1. The participant must have been assigned an ICD-10
diagnosis of Alzheimer’s disease (AD), vascular
dementia, or mixed AD and vascular dementia. AD
accounts for 62% of dementia diagnoses, and
vascular dementia for 17%, with mixed AD and
vascular dementia accounting for a further 10% [2].
These categories together capture 89% of thosediagnosed with dementia. There is no reason to
assume that people with rarer subtypes of dementia,
including dementia with Lewy bodies (4%), fronto-
temporal dementia (2%) and Parkinson’s dementia
(2%), could not benefit from CR, but these forms of
dementia have specific features that would require a
distinct approach. For this reason, and because
numbers are likely to be too small to allow for
subgroup analysis, we are not proposing to include
these groups in the current trial.
2. The participant must be in the early stages of
dementia, as indicated by an MMSE score of 18 or
above. This is to ensure that participants recruited
to the trial have a level of cognitive functioning that
is sufficient to allow them to complete the selected
outcome measures without undue difficulty for the
duration of their participation in the study. Use of a
cutoff point, while inevitably somewhat arbitrary,
provides protection for people who may be overly
burdened by the assessments. The selected cutoff of
a score of 18 on the MMSE is frequently used in
research studies and worked well in the pilot trial.
We have not placed any upper limit on the MMSE
score, since it can be expected that a small
proportion of people meeting diagnostic criteria for
dementia will have high MMSE scores [57].
3. If taking acetylcholinesterase inhibitors, the
participant must have been receiving a stable dose
for 1 month prior to trial entry, and there should be
no intention to change the dose over the period of
participation in the study unless clinically indicated.
This is to ensure that intervention effects are not
confounded by changes in medication status.
4. The participant must have a carer who is willing to
participate. While having a carer is not an essential
prerequisite for receiving a CR intervention, it is
important for the purposes of research to obtain an
informant perspective on the effects of the
intervention, and in this trial carers will be asked to
provide an independent rating of goal performance.
It is also important to determine the effects of the
intervention on carer well-being; positive effects on
the carer are likely to bring added benefits in the
longer term for the person with dementia.
5. The participant must be able to give informed
consent. People in the early stages of dementia are
normally expected to have capacity to consent to
participation. When recruiting participants, the
research team will use a checklist to ensure that all
relevant information is considered and that the
participant is able to give informed consent. While
CR principles may be applied at any stage of
dementia, the intervention to be tested here involves
engaging the person with dementia in a collaborative
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meaningful goals, and therefore the participant
needs to be able to understand this and to make a
positive choice to take part.
Exclusion criteria:
1. Participants will be excluded if they have a prior
history of stroke, brain injury or other significant
neurological condition. Such conditions would be
expected to affect cognitive, behavioural and
emotional functioning, and people who have one of
these conditions prior to developing dementia would
have additional rehabilitation needs. While such
individuals might benefit from CR, their inclusion
would represent a potential confounding factor.
2. Participants will be excluded if they are unable to
speak English. This criterion is applied for practical
reasons, because the standardised outcome measures
we plan to use are only available in English. No
official data are available to indicate what proportion
of the UK population cannot speak English; while it
is estimated that about 3% of the population use a
language other than English at home, with over 100
different languages represented (source: The
National Centre for Languages), many of the
individuals concerned also speak English. The time
and costs involved in translating standardised
measures and providing interpreters for assessment
and therapy sessions would be substantial. However,
we predict that very few individuals would be
excluded from participation because of inability to
communicate in English.
Ethical considerations
The study has been reviewed by the North Wales Re-
search Ethics Committee–West, which issued a
favourable opinion on 25 June 2012 (Reference 12/WA/
0185) and has been approved by the Bangor University
School of Psychology Research Ethics Committee.
Based on previous findings, participants randomised to
receive CR may be expected to derive some benefits in
terms of managing everyday activities and general well-
being. Their caregivers may also be expected to show re-
duced stress and improved well-being. Availability of evi-
dence from a definitive trial may be expected to have a
positive influence on the future provision of interven-
tions to support people with early-stage dementia and
their carers. Previous findings also suggest that partici-
pants randomised to TAU are expected to show little or
no change; thus, they will not be harmed by this alloca-
tion. As the trial will provide the first evidence from a
large-scale trial regarding the benefits of CR, it cannot at
this stage be considered unethical to withhold thistreatment from the control group, and the control group
will still have access to the care typically provided by
memory clinics and GPs, and to voluntary sector services.
There are no known risks or side effects associated with
CR. It is possible that some participants may find it chal-
lenging to confront their difficulties, but the therapist will
provide support as they engage in this process, and the
intervention protocol incorporates attention to managing
emotional reactions. Neither the feasibility studies nor the
pilot trial have suggested that this represents a significant
risk to participants. The research team will be trained to
be alert to any concerns about participants’ well-being. If
there are serious concerns about a participant, these will
be referred, wherever possible with the permission of the
individual concerned and the carer, to the clinician re-
sponsible for the participant’s care.
Participants with early-stage dementia, and carers, will
be fully informed prior to entry into the trial about the
intervention and about the current state of knowledge
regarding possible benefits and risks, and this informa-
tion will be updated if additional evidence becomes
available during the course of their participation.
Informed consent will be obtained from all participants
and carers. People with early-stage dementia are expected
to have the capacity to consent to participation. While
consent provided at the outset provides an initial mandate
for entry to the trial and commencement of trial proce-
dures, consent is an ongoing process, and this is crucial
for psychosocial interventions where participants’ active
engagement is required. Therefore, research assistants and
therapists will be trained to monitor ongoing consent and
to respond appropriately to any indication of a possible
withdrawal of consent. As participants will be in the early
stages of dementia, loss of capacity to consent during the
course of participation is expected to be infrequent. How-
ever, on entry to the trial participants will be asked
whether, should they lose capacity to consent, they are
willing to continue to be included in the trial and to have
their data used.
Personally identifiable information will be retained
only until publication of the trial report unless the par-
ticipant has consented to retention of details for poten-
tial further follow-up, while anonymised data will be
retained for 5 years after publication unless a longer
period is required by the Research Ethics Committee or
other regulatory authorities. Consent forms will be
retained for 25 years following trial closure.
The governance and management of the study will be
undertaken within the Department of Health Research
Governance Framework for Health and Social Care (2nd
edition, 2005). This will ensure the highest standards of
clinical research, covering scientific quality, ethical stan-
dards and all related management issues. The trial will
adhere to the Standard Operating Procedures (SOPs) of
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statistical and regulatory matters. This is not a clinical trial
of an investigational medical product (CTIMP) and there-
fore it does not come under the provisions of the Medi-
cines for Human Use (Clinical Trials) Regulations (2004).
All research staff and therapists will undergo training
in Good Clinical Practice with regard to the conduct of
clinical trials. Trial-specific training requirements will be
addressed throughout the study period and regularly
reviewed. Orientation and project-specific training will
be provided for CLRN, MHRN and NISCHR CRC staff.
Sample size
Power calculations and attrition rates are based on find-
ings from the pilot trial. We wish to confirm the finding
that the primary effectiveness outcome of goal perform-
ance was improved in the treatment group [45]. The dif-
ference observed in the pilot was large (standardised
effect >1 at post-intervention assessment). However, we
also wish to detect any effect sizes in the order of 0.3 for
important secondary outcomes, as we judge that this will
give confirmation of effects that are large enough to
have substantive clinical benefits. For the present study,
intervention length has been increased and now includes
a maintenance phase in order to further strengthen
demonstrable effect sizes in secondary outcomes. We
have elected to be conservative in all aspects of our esti-
mate of power, and we have made a larger estimation of
potential attrition than the <20% observed in that study,
based on the 27% rate observed in the recent REMCARE
trial [59]. To achieve 80% power to detect a medium ef-
fect size of 0.3, with alpha 0.05, in primary and second-
ary outcomes, 175 PwD, with their carers, need to
complete the trial in each arm. Adjusting for potential
attrition, we aim to randomise 480 PwD, each with a
carer. There will be one practitioner involved at each
centre, and we will test for differences between sites in
the analysis. If there is a change of practitioner at one or
more centres during the course of the trial we will also
test for practitioner effects.
Outcome measures
(1) Primary outcome measure
Bangor Goal-Setting Interview (BGSI) The BGSI [52]
provides a structured format for the goal-setting process.
The interview proceeds in three stages. First, relevant
domains of functioning are discussed in turn with a view
to eliciting issues that might form the basis for behav-
ioural goal-setting. For each area, the participant rates
perceived importance of making changes in this area,
and readiness to make changes in this area, on a 1 – 10
scale (where 1 is not at all important/not at all ready
and 10 is extremely important/completely ready). Once
all areas have been discussed, the second stage involvesrevisiting each area in turn and negotiating specific be-
havioural goals that conform to ‘SMART’ principles
(specific, measurable, achievable, realistic and time-
delineated). Additionally, goal attainment indicators are
specified, providing clear descriptors of what would con-
stitute 25%, 50% and 75% goal attainment. In the final
stage of the interview, the participant is asked to rate,
for each of the goals that have been identified, current
performance and satisfaction with performance on a 1 –
10 scale (where 1 is unable to perform/extremely dissat-
isfied and 10 is able to perform perfectly/extremely satis-
fied). Mean scores for performance and satisfaction with
performance across goals are calculated by dividing in
each case the sum of the scores for all goals identified by
the number of goals set. For the present study, details of
the goals identified in the baseline BGSI assessment will
be provided to the therapist for each participant allocated
to the CR condition and will form the starting point for
the therapist’s intervention. At follow-up assessment, the
participant re-rates current performance and satisfaction
with performance for each goal so that changes in ratings
can be examined. The interviewer elicits information
about current performance and uses the previously speci-
fied goal attainment indicators to rate the extent of pro-
gress towards achieving the goal. There is scope within
the interview format for informant ratings to be obtained;
in this study, carer ratings of performance and descrip-
tions of goal attainment will be elicited at baseline and
follow-up for comparison purposes.(2) Secondary outcome measures for participants with
dementia
DEMQOL DEMQOL [60] has been designed to assess
health-related quality of life of people with dementia
across the full range of severity and subtypes, and shows
high internal consistency (Cronbach’s alpha 0.87) and
good test-retest reliability (ICC 0.76) in people with mild
to moderate dementia. It consists of a 28-item
interviewer-administered questionnaire for the person
with dementia and a 31-item interviewer-administered
questionnaire on which the caregiver provides proxy rat-
ings. These may be used together or separately. In this
study, only self-ratings by the person with dementia will
be taken. An algorithm has been developed to generate
quality-adjusted life year (QALY) scores from DEMQOL
scores for use in economic evaluation [61].Generalised Self-Efficacy Scale (GSES) The ten-item
Generalised Self-Efficacy Scale (GSES) [62] was created to
assess a general sense of perceived self-efficacy, the poten-
tial to influence one’s situation through one’s own actions.
Responses are made on a 4-point scale. Responses to all
ten items are summed to yield the final composite score
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0.76 to 0.90 [63].
Hospital Anxiety and Depression Scale (HADS) The
HADS [64] contains 14 items forming two subscales:
anxiety and depression. Each item is rated on a 4-point
scale, giving maximum scores of 21 for anxiety and for
depression. Scores of 11 or more on either subscale are
considered to be a significant ‘case’ of psychological
morbidity, with scores of 8–10 classified as ‘borderline’
and 0–7 ‘normal’. The HADS has been employed and
validated in studies of people with dementia and carers
[65,66].
Brief cognitive assessment battery This will consist of
brief tests of memory, attention and executive function,
suitable for people with early-stage dementia, each taking
less than 5 min to administer: (1) Memory: Rivermead Be-
havioural Memory Test (RBMT) [67], story recall subtest.
The RBMT is a well-established, ecologically valid test of
everyday memory. In the story recall task, the researcher
reads out a short story, similar to a brief report of a news-
worthy event in a daily newspaper, and the participant is
asked for immediate and delayed (after 20 min) recall of
the content. Recall is scored following a standard protocol
(inter-rater reliability > 0.9) with a maximum possible
score of 21 for the immediate and for the delayed compo-
nent. Four equivalent versions are available to permit re-
assessment without the risk of practice effects; practice
effects are not anticipated with test-retest intervals of 3
and 6 months, but as a precaution a different version will
be used at each time point. Raw scores will be used in the
analysis as they provide a greater range than the con-
densed standardised profile score that is used in calcula-
tion of the overall RBMT score. (2) Attention: Test of
Everyday Attention (TEA) [68], elevator counting and ele-
vator counting with distraction subtests. The TEA is a
well-established, ecologically valid test of everyday atten-
tion, with subtests assessing different components of at-
tention. The elevator counting subtest assesses sustained
attention. Participants are required to count a short string
of monotonous tones and give the total number. Seven
strings are presented, and the total score is the number of
strings correctly counted. The elevator counting with dis-
traction subtest assesses auditory selective attention. Fur-
ther strings of tones are presented, this time also including
distractor (high-pitched) tones that are not to be counted.
The total score is the number of strings correctly counted.
Three equivalent versions of each subtest are available to
permit reassessment without the risk of practice effects; as
above, practice effects are not anticipated but as a precau-
tion a different version will be used at each time-point. (3)
Executive function: Letter fluency subtest of the Delis-
Kaplan Executive Function System (D-KEFS) [69]. D-KEFS consists of a set of standardised tests of executive
function. The verbal letter fluency task evaluates the ex-
ecutive subdomains of initiation, response generation and
inhibition [70] and draws on semantic memory and lan-
guage ability. In this task, the participant is asked to list as
many words as possible beginning with a specific letter of
the alphabet in a 1-min period, excluding proper nouns
and repetitions. Three letters, F, A and S, are used. The
total number of correct responses to the three letters is
used in analysis. This task has been extensively examined
in people with early-stage dementia [71]. Evidence sug-
gests that even in healthy participants there are no prac-
tice effects for most components of this task even at test-
retest intervals of less than 2 weeks; there are minimal
practice effects for the switching component with test-
retest intervals of less than 2 weeks, but not with longer
intervals.
(3) Secondary outcome measures for the carer
Relatives’ Stress Scale (RSS) The RSS [72] is a 15-item
dementia-specific measure of caregiver stress with items
rated on a 5-point Likert scale and summed. A higher
overall score indicates higher levels of caregiving-specific
stress.
EuroQOL (EQ5D) The EQ-5D [73] is a standardised
measure of health status and health outcome, applicable
to a wide range of health conditions. In the first section,
the respondent is asked to select one of three options
for each of five dimensions: mobility, self-care, usual ac-
tivities, pain/discomfort and anxiety/depression. For
each dimension, the three response options are coded
on a 3-point scale from 1 (no problem) to 3 (unable to
perform/extreme problem). This yields a descriptive pro-
file (e.g. 11232) across the five dimensions. The second
part of the measure is a visual analogue scale for self-
rating of health-related quality of life (‘your health state
today’). This measure is included because the EQ5D
score will be used to generate QALY scores using soci-
etal weights.
WHO Quality of Life – BREF(WHOQOL-BREF) The
WHOQOL-BREF [74] is a 26-item scale assessing per-
ceived quality of life, giving scores in four domains: en-
vironment, social relationships, psychological and
physical health.
(4) Service utilisation
Client Services Receipt Inventory (CSRI) The CSRI
[75] provides a template that can be adapted to the
needs of each specific study. Respondents are asked
about their use of health care services for a period pre-
ceding baseline assessment and during the study period.
The questions cover contact with a range of health and
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hospital appointments and stays, participation in local
authority funded activities such as day centres, participa-
tion in activities run by voluntary organisations and the
contribution of informal carers. Questions to examine
the nature and extent of any dementia-specific treatment
received from the Memory Clinic will be included.
(5) Demographic and background information for the
person with dementia and carer
Details such as gender, age, relationship between person
with dementia and carer and whether they live together,
age of onset of dementia, educational level, social class
and co-morbidities will be collected. This will allow us
to examine effects of demographic and social variables
on treatment efficacy.
(6) Process measures for the CR group
For the cognitive rehabilitation group, process measures
will be taken to provide convergent evidence about
change in goal performance. In-session parallel ratings
of goal performance by participant, carer and therapist
will be made when each goal is introduced and in ses-
sion 10. A simplified goal attainment scaling procedure
[43] will be applied, as described for the pilot trial;
clearly specified behavioural indicators of full and partial
goal achievement will be defined when each goal is in-
troduced, and progress according to these criteria will be
rated by the therapist following session 10 and again fol-
lowing session 14.
(7) Therapist adherence to protocol
Therapist adherence to the treatment protocol will be
monitored through therapy logs and structured supervi-
sion sessions. Therapists will receive monthly telephone
supervision and face-to-face supervision meetings will
be held every 3 months. Therapy logs reporting session
content (with participant details anonymised) will be
submitted to the supervisor for scrutiny prior to supervi-
sion sessions.
(8) Treatment compliance
Treatment compliance will be indexed by the number of
sessions completed for each participant.
Procedure
Initial identification of participants will be made by Na-
tional Institute for Health Research (NIHR) Comprehen-
sive Local Research Network (CLRN) and Mental Health
Research Network (MHRN) staff in England and Na-
tional Institute of Social Care and Health Research Clin-
ical Research Collaboration (NISCHR CRC) staff in
Wales. Participants will be contacted by or on behalf of
the clinician responsible for their care and invited torespond directly to the research team to express an
interest in finding out more about the study. Interested
participants and carers will then be contacted by tele-
phone by the local research assistant, who will provide
additional information and send out written details. This
will be followed by a further telephone call; for those in-
terested in finding out more, a meeting will be arranged
at which the research assistant will explain the study, an-
swer any questions they may have, re-check eligibility
and ensure that the person with dementia has the cap-
acity to consent. Consent from the participant and the
carer will be taken at, or following, this visit.
At each centre, once participants have given informed
consent, they will be visited by the research assistant
who will conduct the baseline assessment. Following this
assessment, the research assistant will trigger randomisa-
tion. Results of the randomisation will be sent to the
therapist, who will telephone the participant and the
carer to explain the next steps. Participants allocated to
CR will receive 10 weekly visits from the therapist over a
3-month period. The therapist will trigger the post-
intervention assessment for all participants. The re-
search assistant will visit each participant to conduct the
assessment. Following the post-intervention assessment,
participants in the CR group will receive four mainten-
ance sessions with the therapist over a 6-month period.
The research assistant will visit all participants 6 months
after the post-intervention assessment to carry out the
final 6-month follow-up assessment. All primary and
secondary outcome measures, and service utilisation
measures, will be administered at each assessment point.
After consent and baseline assessment, participants
will be individually randomised. Randomisation to
GREAT will be achieved by secure web access to the re-
mote randomisation centre, NWORTH CTU, at Bangor
University. This system will be set up, maintained and
monitored independently of the trial statistician or other
trial staff. The randomisation will be performed by dy-
namic allocation [76] to protect against subversion while
ensuring that the trial maintains good balance to the al-
location ratio of 1:1 both within each stratification vari-
able and across the trial. Participants will be stratified by
centre, gender, age (under 75 vs. 75 and above) and
MMSE score (under 24 vs. 24 and above). For validation
purposes, additional information will be taken including
the participant’s trial number, initials, and date of birth,
and details of the person requesting the randomisation.
This is a single-blind trial. The researchers taking the
measures will be blind to allocation, as will the data ana-
lysts. The importance of maintaining blinding will be
emphasised in the training for both research assistants
and therapists. As the participants are not blind to their
treatment, at post-intervention and follow-up assess-
ments participants will be specifically asked not to
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study and not to reveal to the researcher whether or not
they were visited by the therapist. Following each assess-
ment, the blinded researcher will note to which condi-
tion s/he thought the participant had been allocated and
how certain s/he was of the allocation. Sensitivity ana-
lyses will be performed to determine whether this know-
ledge affected participant scores. If there is evidence to
suggest that consequential bias is present, the analysis
will be adjusted to counteract this effect.
Other protection from bias will include the method of
allocation to groups. The randomisation will be performed
independently of the data analysis team by the CTU using
a dynamic, stratified, web-based system designed to pro-
tect from bias by the unpredictability of the algorithm and
the security of the web-based programme. Blinding will be
maintained by automatic generation of randomisation
codes and distribution via e-mail directly to the therapists
responsible for implementing the treatment. Further bias
protection will come from a “treatment as allocated” ana-
lysis, which will be the principal analysis performed on
both primary and secondary outcomes. Treatment compli-
ance measures will be restricted to inclusion in secondary
analyses.
We will collect basic anonymised demographic data and
reasons for not progressing to trial participation for all
those people identified as warranting screening and invita-
tion to the trial but declining to be screened or to partici-
pate. These data will be reported on a CONSORT
diagram, together with information on the amount and na-
ture of missing data, to enable readers to assess bias arising
from recruitment or acceptability issues within the trial.
Statistical analysis
Demographic and baseline data will be fully described
and all outcome data will be analysed and reported. Sig-
nificance will be assumed to be 5% throughout, and 95%
confidence intervals will be quoted. All data will be
anonymised and coded so that data collection and statis-
tical analysis are blind to treatment allocation. The code
will be broken only after the primary analysis has been
completed. A fully pre-specified analysis plan will be
prepared prior to the data being released to analysts.
The analysis will be performed on a “Treatment as Allo-
cated” principle to ensure protection against unintended
bias. The data will be fully imputed in line with the pre-
defined statistical analysis plan to minimise data loss due
to missing values or time points. Sensitivity analyses
(best case/worst case) will be performed to assess the in-
fluence of differing imputation assumptions. All trial
reporting will be CONSORT-compliant [77].
For each outcome measure, at both post-intervention
and follow-up, three analyses will be presented, the first
two being unadjusted and adjusted treatment-as-allocated analyses and the third a treatment received
analysis:
1. An unadjusted two-sample t-test by allocation group.
2. An analysis of covariance with baseline score and
stratification variables as the covariates and allocated
group as the condition factor. Between-group effect
sizes with confidence intervals will be calculated
using Cohen’s d. Centre will be added as a fixed
factor to test and quantify any site-specific effects,
and if the number of practitioners is greater than
the number of centres, practitioner will be added as
a random factor.
3. A repeat of analysis 2 with treatment compliance
factored in.
If CR is shown to be effective, additional forward step-
ping regression modelling will be undertaken to identify
factors important in maximising the observed effects.
Factors that will be investigated will include diagnostic
category, medication status, educational level, social
class, caregiver relationship to the person with dementia
(spouse, adult child, other), and whether or not the carer
is residing with the person with dementia.
For the cost-effectiveness analysis (CEA), service utilisa-
tion and carer input data will be collected using the CSRI.
Unit costs will be attached to service use measures (from
national reference costs, the PSSRU compendium [78] or
calculated anew), CR costed in liaison with providers, and
carer inputs valued using opportunity and replacement
cost options. The CEA will look at changes over 9 months
from each of two perspectives (health and social care; soci-
etal) in four analyses: cost of achieving an incremental
change in BGSI; cost of achieving incremental changes in
self-efficacy for participants with dementia; cost of achiev-
ing incremental QALY gains for participants with demen-
tia; cost of achieving incremental QALY gains for carers.
Incremental cost-effectiveness ratios will be computed as
required and acceptability curves plotted for a range of
willingness-to-pay values. Net-benefit regressions will
make it possible to control for site, baseline outcome mea-
sures (where appropriate) and baseline costs, as well as
gender, age and MMSE score. Sensitivity analyses will be
conducted to test for different assumptions in the attach-
ment of costs. We will also estimate the investment costs
and net costs to the NHS and the social care system of
making CR available nationally.
Research governance
The research will be sponsored by Bangor University.
The sponsor will ensure that appropriate indemnities are
in place. The research will be overseen by a Trial
Steering Committee and a Data Monitoring and Ethics
Committee. Safety data will be routinely reported to the
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and any suspected unexplained adverse reactions
(SUSARs) noted will be reported to both the DMEC and
the trial sponsor within established timeframes. Given
the nature of the intervention, no interim analyses are
planned, but such analyses may be requested at any time
by the DMEC.
The issue of potentially competing studies will be moni-
tored carefully. At the time of developing the protocol,
only one study that could be perceived as potentially com-
peting had been identified by local networks; that study
was recruiting people with lower MMSE scores, and re-
cruitment was due to be completed by May 2013. GREAT
is a pragmatic trial and therefore participation would not
preclude involvement in other clinical trials per se, unless
those trials involved cognition-focused intervention. How-
ever, participant burden and inclusion/exclusion criteria in
other, fastidious trials may preclude such dual participa-
tion. Each local PI will review any situation where there
may be a conflict of recruitment pathways between trials
to ensure that all potential participants are offered the
most suitable option based on closest fit to eligibility cri-
teria and participant preference.
Service user involvement
Service users have been involved in the feasibility and
pilot stages of the research leading to the development
of this trial. The pilot trial benefitted greatly from the in-
volvement of Alzheimer’s Society Research Network Vol-
unteers. During the development of the present study
we again sought, and took into account, the views of
Alzheimer’s Society Research Network Volunteers and of
service users contributing to the Dementia and Neuro-
degenerative Diseases Research Network (DeNDRoN)
Patient and Public Involvement (PPI) programme. PPI
for the GREAT trial will be provided through a partner-
ship with the Alzheimer’s Society; this will ensure that
service users are fully involved with the design, delivery
and dissemination of the research. Service users will be
consulted at each stage of the trial to ensure optimal tai-
loring of study protocols and procedures. To ensure that
PPI is integrated throughout the study, two service user
representatives will sit on the Trial Steering Committee.
The Alzheimer’s Society Research Network will also con-
tribute to dissemination activities towards the end of the
study, ensuring that outcomes are communicated to lay
audiences and policy-makers.
Implementation within routine health-care provision
This will be the first multi-centre trial of individualised,
goal-oriented cognitive rehabilitation for people with
early-stage dementia. The CR approach offers a practical
means of engaging people with dementia and carers in an
early intervention process that aims to reduce functionaldisability and maximise engagement and participation,
contributing to the possibility of living well with dementia.
This approach can readily be offered by memory clinics in
the period following diagnosis. Several UK memory ser-
vices have already expressed interest in implementing CR.
CR is also becoming acknowledged internationally; for ex-
ample, it has recently been authorised for insurance reim-
bursement in Belgium, and has been conducted with the
aid of trained volunteers in Canada. People with dementia
have themselves begun to advocate for a rehabilitation ap-
proach [79]. The trial will provide the necessary evidence
base to extend these developments, if the findings demon-
strate that CR is indeed both clinically beneficial and cost-
effective. Towards the end of the trial, we will build on the
experience gained at each site to demonstrate how the CR
approach can most effectively be integrated into routine
health-care provision. Once recruitment for the trial
comes to an end, we will develop materials and offer train-
ing for clinical teams and therapists, as well as preparing
information for people with dementia, carers and the gen-
eral public. Information about good practice in this area
will be disseminated through a range of routes.
Trial status
The GREAT trial started on 1 October 2012 and will be
recruiting participants from 1 April 2013 to 30 September
2015. The end date for the trial is 31 December 2016.
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